|

|

close search icon

Company Profile

Corporate Culture

Management Team

Company History

Message from the CEO

Honors and Awards

Over 19 years of experience in R&D

01 Drug Discovery

Chemistry Research

Catalyst Screening

Enzyme Catalysis

Medicinal Chemistry

Synthetic Chemistry

Analytical Chemistry

Full Time Equivalent(FTE)

Fee For Service(FFS)

Biology Research

Structural Biology

Enzymology & Molecular Interactions

Antibody Discovery

Translational Medicine

Computational Biology & Molecular Modeling

Early Pharmacokinetics

Radiolabel ADME

02 Pharmaceutical Research

Active Pharmaceutical Ingredients

Route Selection

Production Process Optimization

Clinical Sample Production

Impurity Traceability & Control

Generic Drug Process Study & Filing

Innovative Drug Process Study & Filing

Pharmaceutical preparation

Consistency Evaluation

Preformulation Study

Formulation Stability Study

GMP-based Clinical Sample Production & Packaging

Pilot-scale Preparation Testing

Laboratory-scale Preparation Testing

Preparation Quality Research

Formulation Technology Research

Analytical Method Development and Quality Control

03 Preclinical Research

Pharmacology & Pharmacodynamics

Digestive System Disease Models

Endocrine & Metabolic Disease Models

Inflammatory & Immune Diseases Models

Neural System Disease Models

Other Disease Models

Ocular Diseases Models

Cardiovascular Model

Drug Safety Evaluation

Pharmacology & Toxicology Study

Safety Pharmacology

Histopathological Study

Clinicopathological Study

Drug Safety Evaluation Basic Information

In Vitro ADME Assays

In Vivo Pharmacokinetic Assays

Macromolecular Drugs Bioanalysis

Micromolecular Drugs Bioanalysis

01 One-stop Integrated Services

Drug Discovery Platform

Pharmaceutical Research Platform

Preclinical Research Services

Chemical Drug Development

One-stop API Process R&D Department

Medicilon's CDMO Service Platform

Pharmaceutical Research CDMO Service Platform

Translational Medicine Platform

GLP-1 New Drug R&D Service

Botanical Drug Preclinical R&D Technology Platform

Antibody R&D Service

02 Innovative Drug Services

ADC R&D Service Platform

PROTAC R&D Service Platform

mRNA Vaccine Bioanalysis Platform

Non-clinical Research for Cellular Immunotherapies

Nucleic Acid Drug R&D Platform

03 Key Technical Services for Drug R&D

Cytokine and Biomarker Detection Platform

Metabolite Identification (MetID) Service Platform

Drug Forming Research Platform

Safety Assessment Lab of Process Chemistry

Flow Cytometry Technology Platform

SEND Format Conversion Platform

Process Department Solid Form Screening Platform

Green Chemistry Platform

Flow Sorting Platform

NanoString nCounter Detection Platform

04 Drug Efficacy Evaluation for Common Diseases

IO Pharmacodynamic Model Evaluation Platform

Pharmacodynamic Evaluation Model Platform for Inflammatory and Immune Diseases

Rodent Cerebrovascular Disease Drug Efficacy Evaluation System

05 Advanced Preparation R&D

Inhalation drug R&D platform

Ophthalmic drug R&D platform

Skin Topical Preparation R&D

06 Drug Analysis

07 Public Services

Intellectual Property Protection

Clients Testimonials

Medicilon Support

U.S.

Address: 50 Soldiers Field Place, Boston, MA 02135 (America)

Tel: +1(626)986-9880

UK

Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK

Tel: 0044 7790 816 954

Email: marketing@medicilon.com

China

Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)

Postcode: 201299

Tel: +86 (21) 5859-1500 (main line)

Fax: +86 (21) 5859-6369

Medicilon Events

Featured Stories

2023-07-27Medicilon Events

The Medicilon DMPK team was praised again, and Dr. Yan Feng, CEO of Leading Tac Pharma, came to present the award

Dr. Yan Feng, CEO of Leading Tac Pharma, came to present the award the Medicilon DMPK team the "Best Partner Award" to express their gratitude and recognition.

2023-07-27Medicilon Events

Fudan University, School of Management "Science and Technology Entrepreneur Camp" entered Medicilon: "Hardcore Technology" as the background color, Adding "luster" to new drug research and development

On July 14, Professor Xiongwen Lu, Dean of the School of Management of Fudan University, led the professor group of Fudan School of Management and the students of the fifth phase of the Fudan Science and Technology Entrepreneur Camp into the Zhangjiang Park of Shanghai Medicilon Inc. (Medicilon) to conduct a site visit.

Stock Information

Investment Contact

Medicilon 688202

RMB

As of Beijing time The data is from a third-party organization and is only for reference.

For actual information, please refer to：www.eastmoney.com

Talent Development

Employee Activities

Campus Recruitment

Social Recruitment

Campus Recruitment

Campus Recruitment

Social Recruitment

Social Recruitment

Close

© 2023 Shanghai Medicilon Inc. All rights reserved Shanghai ICP No.10216606-3

Shanghai Public Network Security File No. 31011502018888 | Website Map

ABOUT
Company Profile Management Team Honors and Awards Corporate Culture

SERVICES
Drug Discovery Pharmaceutical Research Preclinical Research

PLATFORM
One-stop Integrated Services Innovative Drug R&D Services Key Technical Services for Drug R&D Drug Efficacy Evaluation for Common Diseases High-end Preparations Technology Platform Public Services

CLIENT CENTER
Intellectual Property Protection Clients Testimonials Downloads Partnerships Medicilon Support Newsletters

NEWS
Medicilon Events Featured Stories Market Events Videos A.C.E.

INVESTORS
Stock Information Investment Contact

CAREERS
Talent Development Employee Activities Campus Recruitment Social Recruitment

© 2023 Shanghai Medicilon Inc. All rights reserved Shanghai ICP No.10216606-3

Shanghai Public Network Security File No. 31011502018888 |Website Map

关闭

Contact Us

Business Inquiry

Global：

Email:marketing@medicilon.com

+1(626)986-9880(U.S.)

0044 7790 816 954 (Europe)

China：

Email: marketing@medicilon.com.cn

Tel: +86 (21) 5859-1500

Message

Back To Top

Online Message×

Medicilon Events

News and Events

Medicilon Events Featured Stories Market Events Videos A.C.E.

HomenewsMedicilon Events

Medicilon Events

Hot information：

Medicilon Appoints Dr. Liu Jian as President of Drug Discovery Division| Medicilon FTE services & FFS services - flexible and efficient cooperation model| Medicilon appeared at the 25th SAPA-NE Annual Conference

Medicilon appeared at the 25th SAPA-NE Annual Conference

The 25th annual conference of SAPA-NE (Sino-American Pharmaceutical Professionals Association–New England/Boston) was successfully held in Boston, MA. During the conference, the Medicilon team conducted in-depth exchanges with a lot of pharmaceutical colleagues, and discussed about the industry situation and market prospects.

Medicilon appeared at the 25th SAPA-NE Annual Conference

Reelected for 4 consecutive years! Medicilon is on the list of "Top 20 Chinese R&D CRO Enterprises in 2023"

On June 16, 2023, the "2023 Chinese Pharmaceutical CRO Enterprise Ranking" was released. Shanghai Medicilon Inc. was once again shortlisted for the 2023 China Pharmaceutical CRO Enterprise Ranking List.

Reelected for 4 consecutive years! Medicilon is on the list of "Top 20 Chinese R&D CRO Enterprises in 2023"

Medicilon congratulates MindRank's GLP-1RA small molecule oral drug for successfully administering the first subject in clinical phase I

MindRank's GLP-1RA small molecule oral drug has been successfully administered to the first subject in clinical phase I. Medicilon as a strategic partner of MindRank, provided MDR-001 with API process development and preparation R&D services to help speed up its research and development.

Medicilon congratulates MindRank's GLP-1RA small molecule oral drug for successfully administering the first subject in clinical phase I

Medicilon Assists Toll Biotech's TollB-001 tablets, a new class 1.1 drug, to officially approve for clinical trials by the FDA

Recently, the IND application of TollB-001 Tablets, a class 1.1 new drug for rheumatoid arthritis by Toll Biotech, has been officially approved by the FDA. Medicilon provided pharmaceutical research services, including raw materials and preparation, for TollB-001 tablets, which accelerated the research process.

Medicilon Assists Toll Biotech's TollB-001 tablets, a new class 1.1 drug, to officially approve for clinical trials by the FDA

To build an integrated AI platform for early drug discovery and evaluation, Medicilon and DP Technology reached a strategic collaboration

Recently, Shanghai Medicilon Inc. (Medicilon) and DP Technology Ltd. announced the signing of a strategic collaboration agreement. The two parties will work together to build an integrated AI platform for early drug discovery and evaluation based on AI4S.

To build an integrated AI platform for early drug discovery and evaluation, Medicilon and DP Technology reached a strategic collaboration

Medicilon was honored as "2023 Growth Potential Company"

Shanghai Medicilon Inc. (Medicilon) was awarded the "2023 Growth Potential Company" by virtue of its stable and excellent profitability, innovation ability, and competitive strength.

Medicilon was honored as "2023 Growth Potential Company"

Congratulations on the positive phase I clinical results of Raymon Pharma's first Chinese eye drops for the treatment of wAMD

Recently, Raymon Pharma announced that the clinical trial of self-developed RA1115-B1 eye drops for the treatment of neovascular (wet) age-related macular degeneration (wAMD) was launched in China. Medicilon provided pharmaceutical research services such as raw material drug production, raw material drug process development, and preparation prescription process development to accelerate the R&D process.

Congratulations on the positive phase I clinical results of Raymon Pharma's first Chinese eye drops for the treatment of wAMD

Medicilon interview with Dr. Fei Zhang | Walking in the dark with a light, Raymon Pharma's new medicinal technology benefits eye health

Shanghai Medicilon Inc. (Medicilon) has the honor to interview Dr. Fei Zhang, the founder of Raymon Pharma, to share his unique insights in the field of ophthalmic drugs.

Medicilon interview with Dr. Fei Zhang | Walking in the dark with a light, Raymon Pharma's new medicinal technology benefits eye health

Jingxin Pharmaceutical awarded the Medicilon DMPK team and the New Drug Registration Department the "Outstanding Contribution Team Award"

Jingxin awarded the Medicilon DMPK team and the New Drug Registration Department "Outstanding Contribution Team Award" and a letter of thanks.

Jingxin Pharmaceutical awarded the Medicilon DMPK team and the New Drug Registration Department the "Outstanding Contribution Team Award"

Medicilon was honored again the "Top Ten Drug Innovation Service Institutions of the Year" of the Pharmaceutical Innovation Award

Recently, the "3rd Pharmaceutical Innovation Award", was released. Medicilon was honored again the "Top Ten Drug Innovation Service Institutions of the Year".

Medicilon was honored again the "Top Ten Drug Innovation Service Institutions of the Year" of the Pharmaceutical Innovation Award

Congratulations to Gluetacs Therapeutics' new drug clinical research application for GT919, the first molecular glue degradation agent pipeline, approved by the FDA

Recently, Gluetacs Therapeutics (Gluetacs)'s first class 1 new drug, GT919 Capsules, a molecular glue degradation agent pipeline, was approved by the US Food and Drug Administration (FDA) to enter clinical trials. Medicilon's one-stop preclinical R&D service platform empowering new drug research and development.

Congratulations to Gluetacs Therapeutics' new drug clinical research application for GT919, the first molecular glue degradation agent pipeline, approved by the FDA

Medicilon interviewed Academician Biao Jiang | Co-founded Gluetacs Therapeutics to transform the scientific and technological achievements sleeping in the ivory tower

For this reason, Shanghai Medicilon Inc (Medicilon) interviewed Academician Jiang to see how he overcomes the problems of transformation of scientific and technological achievements, how to improve the efficiency of new drug research and development, and how to be a scientist and entrepreneur.

Medicilon interviewed Academician Biao Jiang | Co-founded Gluetacs Therapeutics to transform the scientific and technological achievements sleeping in the ivory tower

prev
1
2
3
4
5
6
7
8
9
10
11
next

Global

Address: 50 Soldiers Field Place, Boston, MA 02135 (America)

Tel: +1(626)986-9880(U.S.)

Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK

Tel: 0044 7790 816 954 (Europe)

Email: marketing@medicilon.com

Address: 5th Floor, 24, Seochojungang-ro 8-gril, Seocho-gu, Seoul, 06643 South Korea

Tel: +82 70-8269-5849

China

Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)

Postcode: 201299

Tel: +86 (21) 5859-1500 (main line)

Fax: +86 (21) 5859-6369

© 2023 Shanghai Medicilon Inc. All rights reserved All Rights Reserved Privacy Policy

-->